Industrial Purity Specifications Dimethyl (3-Oxo-1,3-Dihydroisobenzofuran-1-Yl)Phosphonate
- Verified CAS 61260-15-9: Strict adherence to molecular formula C10H11O5P and MW 242.2 for API intermediates.
- Advanced Analytics: Batch consistency confirmed via HPLC, NMR, and LC-MS profiling prior to shipment.
- Bulk Capability: Scalable manufacturing process supporting commercial-scale procurement and global logistics.
In the landscape of modern pharmaceutical synthesis, the reliability of key building blocks determines the success of downstream API production. Dimethyl (3-oxo-1,3-dihydroisobenzofuran-1-yl)phosphonate, registered under CAS 61260-15-9, serves as a critical intermediate in the manufacture of poly(ADP-ribose) polymerase (PARP) inhibitors. As demand for oncology therapeutics grows, the requirement for industrial purity specifications has become paramount. Procurement teams must evaluate suppliers not only on price but on their ability to maintain consistent stereochemistry and minimize impurities that could affect final drug safety.
At NINGBO INNO PHARMCHEM CO.,LTD., we prioritize technical transparency and process control. This compound, often referred to in technical literature as 3-dimethoxyphosphoryl-3H-2-benzofuran-1-one, requires precise handling during phosphorylation. The structural integrity of the isobenzofuranone ring system is sensitive to hydrolysis and thermal degradation. Therefore, establishing a robust manufacturing process that mitigates these risks is essential for delivering material suitable for Good Manufacturing Practice (GMP) environments.
Defining Industrial-Grade Purity Standards for Pharmaceutical Intermediates
Achieving a purity profile suitable for clinical-stage synthesis requires more than standard recrystallization. The target specification for this phosphonate intermediate typically exceeds 98% purity, with strict limits on residual solvents and heavy metals. Impurities often arise from incomplete phosphorylation or side reactions involving the lactone ring. Advanced purification techniques, such as column chromatography followed by controlled crystallization, are employed to isolate the desired product from byproducts like 3-oxo-1,3-dihydroisobenzofuran-1-ylphosphonic acid derivatives.
When sourcing high-purity Dimethyl (3-oxo-1,3-dihydroisobenzofuran-1-yl)phosphonate, buyers should request detailed impurity profiles. Key parameters include the assessment of residual starting materials and any demethylated species. A reliable global manufacturer will provide data demonstrating that batch-to-batch variation is minimized, ensuring that downstream reaction yields remain predictable. This consistency is vital for scaling from kilogram to multi-ton production without requiring extensive re-optimization of subsequent synthetic steps.
Physical and Chemical Specifications
The following table outlines the standard technical specifications expected for industrial-grade supply. These metrics serve as a baseline for quality assurance agreements between suppliers and pharmaceutical clients.
| Parameter | Specification | Test Method |
|---|---|---|
| CAS Number | 61260-15-9 | Registry Verification |
| Molecular Formula | C10H11O5P | Calculated |
| Molecular Weight | 242.2 g/mol | Mass Spectrometry |
| Purity (HPLC Area %) | ≥ 98.0% | HPLC / UV Detection |
| Appearance | White to Off-White Solid | Visual Inspection |
| Residual Solvents | Compliant with ICH Q3C | GC Headspace |
| Storage Conditions | Room Temperature, Sealed | Stability Study |
Analytical Methods for Verifying ≥98% Purity Compliance
Verification of chemical identity and potency relies on orthogonal analytical techniques. Proton Nuclear Magnetic Resonance (NMR) is utilized to confirm the structural arrangement of the phosphonate ester relative to the lactone ring. Specific attention is paid to the chemical shifts of the methoxy groups and the methine proton at the 1-position of the isobenzofuranone system. Any deviation in these signals can indicate structural isomers or degradation products.
High-Performance Liquid Chromatography (HPLC) provides the quantitative assessment of purity. A robust method will separate the main peak from any related substances with a resolution factor greater than 1.5. Additionally, Liquid Chromatography-Mass Spectrometry (LC-MS) is employed to identify unknown impurities based on their mass-to-charge ratio. This level of scrutiny ensures that the synthesis route employed did not introduce persistent contaminants that could carry through to the final Active Pharmaceutical Ingredient (API).
Role of COA in Ensuring Batch Consistency for API Synthesis
The Certificate of Analysis (COA) is the definitive document governing the acceptance of chemical materials in a regulated supply chain. For intermediates used in oncology drug production, the COA must include comprehensive data on assay, identity, and impurities. It serves as a legal and technical guarantee that the material meets the agreed-upon specifications. Without a valid COA, integrating a new batch into an existing synthesis route poses significant regulatory and technical risks.
Furthermore, the COA should reflect stability data indicating how the material behaves under recommended storage conditions. Phosphonate esters can be susceptible to hydrolysis if exposed to moisture over extended periods. Therefore, packaging integrity and desiccant usage are critical components of the delivery specification. Clients should verify that the COA includes batch numbers traceable to raw material inputs, ensuring full transparency in the supply chain.
Commercial Viability and Bulk Procurement
Beyond technical specifications, commercial terms play a decisive role in supplier selection. The bulk price of specialized intermediates is influenced by raw material availability, process complexity, and scale. Efficient manufacturing processes that maximize yield while minimizing waste contribute to competitive pricing without compromising quality. Suppliers capable of producing multi-kilogram quantities consistently offer a strategic advantage to pharmaceutical companies aiming to secure their supply chains against market volatility.
Logistics and support are equally important. Reliable partners provide technical support for integration, offering data on solubility and reactivity to assist process chemists. For instance, knowing that the product is soluble in DMSO or specific organic solvents aids in reaction setup. NINGBO INNO PHARMCHEM CO.,LTD. maintains a commitment to supporting clients with detailed technical documentation and responsive service, ensuring that procurement is seamless from inquiry to delivery.
Conclusion
The production of high-quality Dimethyl (3-oxo-1,3-dihydroisobenzofuran-1-yl)phosphonate requires a synergy of advanced chemistry, rigorous quality control, and reliable logistics. By adhering to strict industrial purity standards and providing comprehensive analytical data, manufacturers enable the safe and effective development of life-saving medications. Procurement professionals should prioritize partners who demonstrate transparency in their manufacturing process and a proven track record of delivering consistent, high-purity intermediates for global pharmaceutical applications.